- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04336722
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Ipsen Clinical Study Enquiries
- Phone Number: see email
- Email: clinical.trials@ipsen.com
Study Locations
-
-
-
Parkville, Australia, 3052
- Recruiting
- Royal Children's Hospital
-
Contact:
- Winita Hardikar, PhD
-
Sydney, Australia
- Recruiting
- The Children´s Hospital at Westmead
-
Contact:
- Michael Stormon, MD
-
-
-
-
-
Gent, Belgium
- Recruiting
- UZ Gent
-
Contact:
- Ruth De Bruyne, MD, PhD
-
-
-
-
-
Montréal, Canada
- Recruiting
- CHU Sainte-Justine
-
Contact:
- Fernando Alvarez, MD
-
Toronto, Canada
- Recruiting
- The Hospital for Sick Children
-
Contact:
- Vicky Ng, MD
-
-
-
-
-
Shanghai, China
- Active, not recruiting
- Children's Hospital of Fudan University
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Guangzhou Women and Children's Medical Center
-
Contact:
- Jiakang Yu
-
-
-
-
-
Bron, France
- Recruiting
- Hôpital Femme Mère Enfant
-
Contact:
- Mathias Ruiz, MD
-
Le Kremlin-Bicêtre, France
- Recruiting
- Bicetre Hospital
-
Contact:
- Emmanuel Gonzales, MD, PhD
-
Lille, France
- Recruiting
- Jeanne de Flandre Hospital
-
Contact:
- Madeleine Aumar, MD
-
Paris, France
- Recruiting
- Necker University Hospital - Enfants malades
-
Contact:
- Florence Lacaille, MD
-
-
-
-
-
Berlin, Germany
- Recruiting
- Charite - Universitatsmedizin Berlin
-
Contact:
- Philip Bufler, MD
-
Hamburg, Germany
- Recruiting
- University Medical Center Hamburg-Eppendorf UKE
-
Contact:
- Konrad Reinshagen, MD
-
Hanover, Germany
- Recruiting
- Hannover Medical School
-
Contact:
- Ulrich Baumann, MD
-
Tuebingen, Germany
- Recruiting
- University Children´s Hospital Tuebingen
-
Contact:
- Ekkehard Sturm, MD, PhD
-
-
-
-
-
Budapest, Hungary
- Recruiting
- Semmelweis Egyetem I.sz Gyermekgyógyászati Klinika
-
Contact:
- Antal Dezsöfi, MD, PhD
-
-
-
-
-
Petah tikva, Israel
- Recruiting
- Schneider Children´s Medical Center of Israel
-
Contact:
- Orith Waisbourd-Zinman, MD
-
-
-
-
-
Bergamo, Italy
- Recruiting
- Asst Papa Giovanni Xxiii
-
Contact:
- Lorenzo D'Antiga, MD
-
Florence, Italy
- Recruiting
- Meyer Children´s University Hospital
-
Contact:
- Giuseppe Indolfi, MD, PhD
-
Padova, Italy
- Recruiting
- University Hospital of Padova
-
Contact:
- Mara Cananzi, MD, PhD
-
Palermo, Italy
- Recruiting
- ISMETT - Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
-
Contact:
- Silvia Riva, MD
-
Roma, Italy
- Recruiting
- Ospedale Pediatrico Bambino Gesù
-
Contact:
- Giuseppe Maggiore, MD
-
Turin, Italy
- Recruiting
- Regina Margherita Children´s Hospital
-
Contact:
- Pier Luigi Calvo, MD
-
-
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Samsung Medical Center
-
Contact:
- Yon Ho Choe, MD
-
Seoul, Korea, Republic of
- Recruiting
- Seoul National University Children's Hospital
-
Contact:
- Joong Kee Youn, MD
-
Principal Investigator:
- Joong Kee Youn, MD
-
-
-
-
-
Kota Bharu, Malaysia
- Recruiting
- Hospital Raja Perempuan Zainab II
-
Contact:
- Wan Mohd Ruzaimie Wan Mohamad Noor, MD
-
Kuala Lumpur, Malaysia
- Recruiting
- University of Malaya Medical Centre
-
Contact:
- Way Seah Lee, MD
-
-
-
-
-
Groningen, Netherlands
- Recruiting
- University Medical Center Groningen
-
Contact:
- Hendrik Jan Verkade, MD, PhD
-
-
-
-
-
Auckland, New Zealand
- Recruiting
- Starship Child Health
-
Contact:
- Helen Evans, MD
-
-
-
-
-
Warsaw, Poland
- Recruiting
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
Contact:
- Piotr Czubkowski, MD, PhD
-
-
-
-
-
Barcelona, Spain
- Recruiting
- Hospital Universitari Vall d'Hebron
-
Contact:
- Jesús Quintero, MD, PhD
-
-
-
-
-
Taipei, Taiwan
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Huey-Ling Chen, PhD, MD
-
-
-
-
-
Ankara, Turkey
- Recruiting
- Hacettepe University Ihsan Dogramaci Childrens Hospital
-
Contact:
- Hasan Özen, MD
-
Antalya, Turkey
- Recruiting
- Akdeniz University Medical Faculty
-
Contact:
- Reha Artan, MD
-
Istanbul, Turkey
- Recruiting
- Istanbul University, Istanbul Medical Faculty
-
Contact:
- Ozlem Durmaz, MD
-
-
-
-
-
Birmingham, United Kingdom
- Recruiting
- Birmingham Women´s and Children´s Hospital
-
Contact:
- Chayarani Kelgeri, MD
-
Leeds, United Kingdom
- Recruiting
- Leeds General Infirmary
-
Contact:
- Naved Alizai
-
-
-
-
California
-
Los Angeles, California, United States, 90027
- Recruiting
- Children's Hospital Los Angeles
-
Contact:
- Rohit Kohli, MD
-
Palo Alto, California, United States, 94304
- Recruiting
- Stanford Children's Health
-
Contact:
- Amrita Narang, MD
-
San Diego, California, United States, 92123
- Recruiting
- Rady Children's Hospital
-
Contact:
- Laura Bauman, MD
-
San Francisco, California, United States, 94158
- Recruiting
- UCSF Benioff Children's Hospital San Francisco
-
Contact:
- Phillip Rosenthal, MD
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
Contact:
- Shikha Sundaram, MD
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Recruiting
- Nemours/Alfred I. DuPont Hospital for Children
-
Contact:
- Adebowale Adeyemi, MD
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Terminated
- Children's National Medical Center
-
-
Florida
-
Miami, Florida, United States, 33146
- Recruiting
- University of Miami
-
Contact:
- Jennifer Garcia, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Children's Healthcare of Atlanta - Emory University School of Medicine
-
Contact:
- Saul Karpen, MD, PhD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Ann & Robert H. Lurie Children's Hospital
-
Contact:
- Alyssa Kriegermeier, MD
-
Principal Investigator:
- Alyssa Kriegermeier, MD
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University School of Medicine
-
Contact:
- Jean Molleston, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins Children's Center
-
Contact:
- Wikrom Karnsakul, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Contact:
- Andrew Wehrman, MD
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan Children's Hospital
-
Contact:
- Maclovio Lopez, MD
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Recruiting
- Children's Mercy Hospital
-
Contact:
- Ryan Fischer, MD
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University in St. Louis
-
Contact:
- Janis M. Stoll, MD
-
-
New York
-
Bronx, New York, United States, 10467
- Recruiting
- The Children's Hospital at Montefiore
-
Contact:
- Pan Debra, MD
-
Principal Investigator:
- Pan Debra, MD
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Jaime Chu, MD
-
New York, New York, United States, 10016
- Recruiting
- NYU Grossman School of Medicine
-
Contact:
- Nadia Ovchinsky, MD
-
Principal Investigator:
- Nadia Ovchinsky
-
New York, New York, United States, 10032
- Recruiting
- NewYork-Presbyterian Morgan Stanley Children's Hospital
-
Contact:
- Dana Goldner, MD
-
Principal Investigator:
- Dana Goldner, MD
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital
-
Contact:
- Michael Rogers, MD
-
Principal Investigator:
- Michael Rogers, MD
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Vera Hupertz, MD
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health & Science University
-
Contact:
- Henry Lin, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- The Children´s Hospital of Philadelphia
-
Contact:
- Kathleen Loomes, MD
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- UPMC Children's Hospital of Pittsburgh
-
Contact:
- James Squires, MD
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- UT Southwestern Medical Center
-
Contact:
- Amal Aqul, MD
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Recruiting
- University of Utah
-
Contact:
- Kyle Jensen, MD
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Contact:
- Evelyn Hsu, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Terminated
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A male or female patient with a clinical diagnosis of BA
- Age at Kasai HPE ≤90 days
- Eligible to start study treatment within 3 weeks post-Kasai HPE
Key Exclusion Criteria:
- Patients with intractable ascites
- Ileal resection surgery
- ALT ≥10× upper limit of normal (ULN) at screening
- Patients reliant only on total parenteral nutrition, or not able to take study medication orally, at randomization
- Acute ascending cholangitis (patients may be randomized after resolution of acute ascending cholangitis)
- Choledochal cystic disease
- INR >1.6 (the patient may be treated with Vitamin K intravenously; sample may be redrawn and if INR is ≤1.6 at resampling the patient may be randomized)
- Any other conditions or abnormalities, including congenital abnormalities, major cardiac surgery, hepatic, biliary, or GI disease which, in the opinion of the Investigator or Medical Monitor, may compromise the safety of the patient, the integrity of study results, or patient compliance with study requirements
- Weight <3.5kg at randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Odevixibat (A4250)
Capsules for oral administration once daily for 104 weeks.
|
Odevixibat is a small molecule and selective inhibitor of IBAT.
|
Placebo Comparator: Placebo
Capsules for oral administration (to match active) once daily for 104 weeks.
|
Placebo identical in appearance to experimental drug (odevixibat).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time from randomization to first occurrence of liver transplant, or death
Time Frame: From baseline to Week 104
|
From baseline to Week 104
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to onset of any sentinel events
Time Frame: From baseline to Week 104
|
Time to onset of any sentinel events
|
From baseline to Week 104
|
Time to pediatric end-stage liver disease (PELD) score >15
Time Frame: From baseline to Week 104
|
Time to pediatric end-stage liver disease (PELD) score >15
|
From baseline to Week 104
|
Total bilirubin levels
Time Frame: From baseline to Weeks 13, 26, 52 and 104
|
Total bilirubin level after 13, 26, 52, and 104 weeks of study treatment
|
From baseline to Weeks 13, 26, 52 and 104
|
Serum bile acid levels
Time Frame: From baseline to Weeks 13, 26, 52 and 104
|
Serum bile acid level after 13, 26, 52, and 104 weeks of study treatment
|
From baseline to Weeks 13, 26, 52 and 104
|
Percentage of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From baseline to Week 104
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
|
From baseline to Week 104
|
Percentage of participants with clinically significant changes in Physical Examination
Time Frame: From baseline to Week 104
|
Percentage of participants with clinically significant changes in physical examination findings will be reported.
The clinical significance will be graded by the investigator.
|
From baseline to Week 104
|
Percentage of participants with clinically significant changes in Laboratory Parameters (blood chemistry, hematology and coagulation)
Time Frame: From baseline to Week 104
|
Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported.
The clinical significance will be decided by the investigator.
|
From baseline to Week 104
|
Percentage of participants with clinically significant changes in Abdominal Ultrasound findings
Time Frame: From baseline to Week 26 and Week 104
|
Percentage of participants with clinically significant change in Abdominal Ultrasound findings will be reported.
The clinical significance will be decided by the investigator.
|
From baseline to Week 26 and Week 104
|
Proportion of patients with liver transplant
Time Frame: From baseline to Week 104
|
Proportion of patients who are alive and have not undergone a liver transplant
|
From baseline to Week 104
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ipsen Medical Director, Ipsen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A4250-011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Atresia
-
Sarah Magdy AbdelmohsenCompleted
-
RenJi HospitalUnknownBiliary Atresia Intrahepatic Syndromic FormChina
-
Children's Hospital of Fudan UniversityCompletedBiliary Atresia Congenital Type 3China
-
Yonsei UniversityCompletedBiliary Atresia, Kasai Portoenterostomy Status
-
Institute of Liver and Biliary Sciences, IndiaUnknownPortal Hypertension, Biliary AtresiaIndia
-
Intercept PharmaceuticalsNot yet recruiting
-
Weibing TangRecruiting
-
Holterman, Ai-Xuan, M.D.T Rose Clinical, Inc.; Big Leap Research; Prometheus USARecruitingBiliary AtresiaUnited States, Vietnam, Pakistan
-
Arbor Research Collaborative for HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
AlbireoEnrolling by invitationBiliary AtresiaSpain, United States, Netherlands, Malaysia, Canada, Germany, Turkey, Italy, France, Australia, Poland, New Zealand
Clinical Trials on Odevixibat
-
AlbireoApproved for marketingProgressive Familial Intrahepatic CholestasisUnited States
-
AlbireoActive, not recruitingAlagille SyndromeUnited Kingdom, United States, France, Germany, Netherlands, Italy, Belgium, Malaysia, Poland, Turkey
-
AlbireoActive, not recruitingProgressive Familial Intrahepatic CholestasisUnited States, Spain, Netherlands, United Kingdom, Turkey, Canada, Italy, Germany, France, Israel, Australia, Belgium, Poland, Saudi Arabia, Sweden
-
AlbireoCompletedAlagille SyndromeUnited States, United Kingdom, France, Germany, Canada, Netherlands, Italy, Malaysia, Belgium, Israel, New Zealand, Poland, Turkey
-
AlbireoCompletedPFIC1 | PFIC2United States, Spain, Netherlands, United Kingdom, Turkey, Canada, Belgium, Italy, Germany, Saudi Arabia, France, Israel, Australia, Sweden, Poland
-
AlbireoEnrolling by invitationBiliary AtresiaSpain, United States, Netherlands, Malaysia, Canada, Germany, Turkey, Italy, France, Australia, Poland, New Zealand
-
Shanghai Ark Biopharmaceutical Co., Ltd.Not yet recruiting